Updated time: 2021-08-02 10:48:06
11A-1090805
2021-08-02
Patent filing
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with a global prevalence ~25%. NAFLD covers a spectrum of disease from steatosis to nonalcoholic steatohepatitis (NASH) and is linked to other metabolic syndromes such as cardiovascular disorder, type II diabetes and hypertension. NAFLD is characterized by increased liver fat content and autophagy represents one mechanism to degrade lipid droplet, an organelle for fat storage. Our study identified a novel autophagy promoting factor TRABID, which stabilizes autophagy key player VPS34 through deubiquitination. Using a mouse model of NAFLD, we found that delivery a TRABID via adeno-associated virus during the progress of NAFLD greatly alleviates disease-related symptoms. This finding indicates that TRABID gene delivery could be used for treating NAFLD.
- Drug for specifically treating NAFLD is currently not available. Our discovery of gene therapy would hold a promise for the treatment of this common disorder.
- nonalcoholic steatohepatitis (NASH)
Ruey-Hwa Chen, Yu-Hsuan Chen, Tzu-Yu Huang, Wen-Hsin Li, Ting-Fen Tsai, Zhao-Qing Shen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

TRABID gene delivery as a strategy to combat nonalcoholic fatty liver disease.